Differences

This shows you the differences between two versions of the page.

--- home:diseases:osteoarthritis [01.05.2019] – [Evidence of infectious cause] sallieq
+++ home:diseases:osteoarthritis [01.05.2019] – [Research] sallieq
@@ Line 13: / Line 13: @@
 Since studies are now showing that tetracycline can slow down the OA process, this suggests that this process is impacted by bacteria. I suspect that lost cartilage will not be replaced but that eliminating CWD bacteria might halt the degenerative process.
-The almost universal use of methotrexate and the rapid development of potent biologic agents have eclipsed the potential usage of TETs for RA. Ironically, it is in osteoarthritis, where there has only been one clinical trial which essentially failed, that the best potential exists for use of an MMP-inhibiting TET.   (({{pubmed>long:21723947}}))
+<blockquote>The almost universal use of methotrexate and the rapid development of potent biologic agents have eclipsed the potential usage of TETs for RA. Ironically, it is in osteoarthritis, where there has only been one clinical trial which essentially failed, that the best potential exists for use of an MMP-inhibiting TET.   (({{pubmed>long:21723947}}))</blockquote>
@@ Line 53: / Line 53: @@
 Altogether, our data show that tetracyclines have no inhibitory potential on any proteoglycanolytic activities within mild or moderately affected human OA cartilage at therapeutic achievable plasma levels.    (({{pubmed>long:20069635}}))
+Biomarkers of early stage osteoarthritis, rheumatoid arthritis and musculoskeletal health.  (({{pubmed>long:25788417}}))
 {{tag>disease incomplete}}

home/diseases/osteoarthritis.txt · Last modified: 09.14.2022 by 127.0.0.1